MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs
MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today
MaxCyte is letting a big medical company called Genentech use its cell-engineering technology to help make new medicines. This shows other companies trust MaxCyte's tools, which could be good for the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.